AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27756277 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (comparison)
Number of subjects: 0
Study 23064254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative energy intake <689 kcal (average 63 kcal/kg/d)
Number of subjects: 32
Study 23064254 — intervention group
Group type: COMPARATOR
Intervention: Cumulative energy intake ≥689 kcal
Number of subjects: 32
Study 20074020 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (20 mg/d)
Number of subjects: 48
Study 20074020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20074020 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 48
Study 18198271 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use during follow-up
Number of subjects: 1191
Study 18198271 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1191
Study 18198271 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rapid cycling status
Number of subjects: 1191
Study 16617647 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Seal laryngeal mask airway
Number of subjects: 35
Study 16617647 — intervention group
Group type: COMPARATOR
Intervention: Reusable laryngeal mask airway
Number of subjects: 35
Study 12519797 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of acupuncture
Number of subjects: 17
Study 12519797 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of herbal medicines
Number of subjects: 17
Study 12519797 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of homeopathy
Number of subjects: 17
Study 12519797 — intervention group
Group type: COMPARATOR
Intervention: Inclusion criteria
Number of subjects: 17
Study 12519797 — intervention group
Group type: COMPARATOR
Intervention: Literature searching methods
Number of subjects: 17
Study 10958089 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% followed by ropivacaine 0.1% + 2 microg x ml(‐1) fentanyl infusion
Number of subjects: 100
Study 10958089 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% followed by bupivacaine 0.125% + 2 microg x ml(‐1) fentanyl infusion
Number of subjects: 100
Study 8659763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 19)
Number of subjects: 37
Study 8659763 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (n = 18)
Number of subjects: 37
Study 8659763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 10) in patients with impaired left ventricular function
Number of subjects: 37
Study 8659763 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (n = 10) in patients with impaired left ventricular function
Number of subjects: 37
Study 8659763 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg T3 (n = 8) in patients with delayed organ harvesting
Number of subjects: 37
Study 8659763 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (n = 9) in patients with delayed organ harvesting
Number of subjects: 37
Study 1579324 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (75 mg) alone
Number of subjects: 50
Study 1579324 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (75 mg) with testosterone (100 mg)
Number of subjects: 50
Study 1579324 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 untreated women)
Number of subjects: 50
Study 3536248 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine scrub and paint
Number of subjects: 101
Study 3536248 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine painting alone
Number of subjects: 101
Study 3536248 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hexachlorophene showers
Number of subjects: 101
Study 30175142 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-gender games (SGG) for girls
Number of subjects: 134
Study 30175142 — intervention group
Group type: COMPARATOR
Intervention: Mixed-gender games for girls
Number of subjects: 134
Study 30175142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-gender games for boys
Number of subjects: 134
Study 30175142 — intervention group
Group type: EXPERIMENTAL
Intervention: 2v2 small-sided games (SSG)
Number of subjects: 134
Study 30175142 — intervention group
Group type: EXPERIMENTAL
Intervention: 4v4 small-sided games (SSG)
Number of subjects: 134
Study 30175142 — intervention group
Group type: COMPARATOR
Intervention: 12v12 large-sided games (LSG)
Number of subjects: 134
Study 26475356 — intervention group
Group type: EXPERIMENTAL
Intervention: Q3W group (capecitabine 1,000 mg/m² twice daily on days 1-14 and oxaliplatin 130 mg/m² on day 1 every 21 days)
Number of subjects: 46
Study 26475356 — intervention group
Group type: COMPARATOR
Intervention: Q2W group (capecitabine 2,000 mg/m² twice daily on days 1-7 and oxaliplatin 85 mg/m² on day 1 every 14 days)
Number of subjects: 46
Study 26475356 — intervention group
Group type: EXPERIMENTAL
Intervention: Q3W group
Number of subjects: 46
Study 26475356 — intervention group
Group type: COMPARATOR
Intervention: Q2W group
Number of subjects: 46
Study 25087417 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation using The Vest clearance system
Number of subjects: 30
Study 22441532 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 813
Study 22441532 — intervention group
Group type: COMPARATOR
Intervention: White Light Imaging (WLI)
Number of subjects: 813
Study 20453564 — intervention group
Group type: EXPERIMENTAL
Intervention: Error reporting promoting strategy (experimental group)
Number of subjects: 0
Study 20453564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 18328059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream applied to the right hemi-face, twice daily for 4 weeks
Number of subjects: 25
Study 18328059 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the left hemi-face, twice daily for 4 weeks
Number of subjects: 25
Study 19143948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown presence during preoperative period
Number of subjects: 0
Study 19143948 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg x kg(‐1) oral 30 min before surgery (max 15 mg)
Number of subjects: 0
Study 19143948 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 15870633 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 27
Study 15870633 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study 11376505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol in continuous infusion (dose 12 mg/h)
Number of subjects: 60
Study 11376505 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac in continuous infusion
Number of subjects: 60
Study 11376505 — intervention group
Group type: COMPARATOR
Intervention: Tramadol in repeated boluses
Number of subjects: 60
Study 11376505 — intervention group
Group type: COMPARATOR
Intervention: Morphine in repeated boluses
Number of subjects: 60
Study 9391249 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) infusion (66 mumol/kg/h for 10 min followed by 22 mumol/kg/h)
Number of subjects: 6
Study 9391249 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) infusion
Number of subjects: 6
Study 9391249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8203853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (400 mg every 8 h)
Number of subjects: 405
Study 8203853 — intervention group
Group type: COMPARATOR
Intervention: Imipenem (1,000 mg every 8 h)
Number of subjects: 405
Study 2962087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone (group A)
Number of subjects: 78
Study 2962087 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic ceftriaxone (group B)
Number of subjects: 78
Study 2962087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 12172398 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 63
Study 12172398 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 29037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking of dietary diversity score (DDS)
Number of subjects: 229
Study 29037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal frequency
Number of subjects: 229
Study 29037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of Fe-rich foods
Number of subjects: 229
Study 29037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of vitamin A-rich foods
Number of subjects: 229
Study 29037267 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic status
Number of subjects: 229
Study 26833933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic strategies for managing behavioral symptoms
Number of subjects: 110
Study 25475461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremote community hospitals
Number of subjects: 0
Study 25475461 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote community hospitals
Number of subjects: 0
Study 25475461 — intervention group
Group type: COMPARATOR
Intervention: Tertiary care hospitals
Number of subjects: 0
Study 22452413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (n = 23)
Number of subjects: 51
Study 22452413 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 28)
Number of subjects: 51
Study 19896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic alignment in OA group
Number of subjects: 34
Study 19896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee adduction moment (KAM)
Number of subjects: 34
Study 19896383 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life, habitual level of physical activity, lower extremity muscle strength and balance performance
Number of subjects: 34
Study 18305231 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 118
Study 18305231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 15909670 — intervention group
Group type: EXPERIMENTAL
Intervention: Castor oil
Number of subjects: 155
Study 15909670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 155
Study 15909670 — intervention group
Group type: COMPARATOR
Intervention: Comparison of castor oil and bisacodyl
Number of subjects: 155
Study 12885750 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPS
Number of subjects: 19
Study 12885750 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa (as a control)
Number of subjects: 19
Study 9876215 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day donepezil
Number of subjects: 0
Study 9876215 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day donepezil
Number of subjects: 0
Study 9876215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7583508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of mentally retarded children
Number of subjects: 40
Study 7583508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with neurological impairments
Number of subjects: 40
Study 7583508 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of parents of children without disabilities
Number of subjects: 40
Study 7583508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of disabled children (both groups)
Number of subjects: 40
Study 1787894 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg/die, one 100 mg tablet twice a day) for 60 days
Number of subjects: 20
Study 1787894 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 20
Study 7270721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-warming group (migraine patients)
Number of subjects: 20
Study 7270721 — intervention group
Group type: COMPARATOR
Intervention: Hand-cooling group (migraine patients)
Number of subjects: 20
Study 7270721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-warming group (normal volunteers)
Number of subjects: 20
Study 7270721 — intervention group
Group type: COMPARATOR
Intervention: Hand-cooling group (normal volunteers)
Number of subjects: 20
Study 30165171 — intervention group
Group type: EXPERIMENTAL
Intervention: FMX101 4%
Number of subjects: 961
Study 30165171 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 961
Study 30091716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough sound analysis
Number of subjects: 322
Study 27123448 — intervention group
Group type: EXPERIMENTAL
Intervention: RAT + real tDCS
Number of subjects: 23
Study 27123448 — intervention group
Group type: COMPARATOR
Intervention: RAT + sham-tDCS
Number of subjects: 23
Study 24825596 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise training
Number of subjects: 94
Study 24825596 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise training
Number of subjects: 94
Study 22301528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 110
Study 22301528 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 110
Study 22301528 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 110
Study 22301528 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 110
Study 20482825 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening with prior consultation either by telephone or outpatient clinic (5,000 persons)
Number of subjects: 7500
Study 20482825 — intervention group
Group type: COMPARATOR
Intervention: CT colonography screening (2,500 persons)
Number of subjects: 7500
Study 20482825 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy following CT colonography positives
Number of subjects: 7500
Study 20482825 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 7500
Study 18572993 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual SMT
Number of subjects: 82
Study 18572993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SMT
Number of subjects: 82
Study 18572993 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 82
Study 15740544 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 450
Study 15740544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 15271871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 58
Study 15271871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11002380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63
Study 11002380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63
Study 11002380 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g/day of n-3 PUFA for 8 weeks
Number of subjects: 63
Study 11002380 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day of n-3 PUFA for 8 weeks (placebo)
Number of subjects: 63
Study 9496777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute attack drugs (sumatriptan, ergot derivatives, NSAIDs)
Number of subjects: 0
Study 9496777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent prophylaxis with ergot derivatives or NSAIDs
Number of subjects: 0
Study 9496777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen supplementation with percutaneous or transdermal oestradiol (100 microg patches)
Number of subjects: 0
Study 9496777 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioestrogen agents (danazol, tamoxifen)
Number of subjects: 0
Study 1526079 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisimultaneous method
Number of subjects: 8
Study 1526079 — intervention group
Group type: COMPARATOR
Intervention: Stable isotope method
Number of subjects: 8
Study 4014808 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 90
Study 4014808 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90
Study 4014808 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium chloride (in patients with widened QRS or ischemic changes)
Number of subjects: 90
Study 4014808 — intervention group
Group type: COMPARATOR
Intervention: No calcium chloride (in patients with widened QRS or ischemic changes)
Number of subjects: 90
Study 31320290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Number of subjects: 17
Study 31320290 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 17
Study 30027483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol (FP)
Number of subjects: 50
Study 30027483 — intervention group
Group type: COMPARATOR
Intervention: Regular protocol (RP)
Number of subjects: 50
Study 27301741 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Based Financing (PBF) scheme applied to malnutrition services in half of the health centres
Number of subjects: 6480
Study 27301741 — intervention group
Group type: COMPARATOR
Intervention: Budget allocation for malnutrition services in the other half of the health centres (Control)
Number of subjects: 6480
Study 24767671 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week programme of exercise (3 sessions per week: 2 supervised, 1 unsupervised)
Number of subjects: 0
Study 24767671 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 22228235 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine
Number of subjects: 3994
Study 20413081 — intervention group
Group type: EXPERIMENTAL
Intervention: CD (youth intervention delivered by CD-ROM)
Number of subjects: 0
Study 20413081 — intervention group
Group type: EXPERIMENTAL
Intervention: CD(P) (youth intervention plus parent intervention)
Number of subjects: 0
Study 20413081 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 18616687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI) with naltrexone
Number of subjects: 1226
Study 18616687 — intervention group
Group type: COMPARATOR
Intervention: Medical Management (MM) plus placebo
Number of subjects: 1226
Study 18616687 — intervention group
Group type: COMPARATOR
Intervention: Combined Behavioral Intervention (CBI) with placebo
Number of subjects: 1226
Study 18616687 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with CBI
Number of subjects: 1226
Study 18616687 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone without CBI
Number of subjects: 1226
Study 16163639 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir
Number of subjects: 70
Study 16163639 — intervention group
Group type: COMPARATOR
Intervention: nelfinavir
Number of subjects: 70
Study 12088971 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral position
Number of subjects: 20
Study 12088971 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally rotated position
Number of subjects: 20
Study 9656287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle video
Number of subjects: 12
Study 9656287 — intervention group
Group type: COMPARATOR
Intervention: No video
Number of subjects: 12
Study 8086325 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 250
Study 8086325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 mg
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril intravenous 5 micrograms kg‐1
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril intravenous 20 micrograms kg‐1
Number of subjects: 0
Study 2527532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril repeated administration for 8 days
Number of subjects: 0
Study 63744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression of the arms during and after surgery
Number of subjects: 0
Study 63744 — intervention group
Group type: COMPARATOR
Intervention: Control patients (no intervention)
Number of subjects: 0
Study 63744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression of the arms
Number of subjects: 0
Study 29617758 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment
Number of subjects: 99
Study 29617758 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - untreated
Number of subjects: 99
Study 26486851 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% energy deficit by calorie restriction alone (CR)
Number of subjects: 24
Study 26486851 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% energy deficit by calorie restriction with structured exercise (CREX)
Number of subjects: 24
Study 26486851 — intervention group
Group type: COMPARATOR
Intervention: weight maintenance (control)
Number of subjects: 24
Study 24810863 — intervention group
Group type: EXPERIMENTAL
Intervention: PFIT‐s
Number of subjects: 51
Study 24810863 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC sum score
Number of subjects: 51
Study 24810863 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength test
Number of subjects: 51
Study 24810863 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline test with ICU discharge
Number of subjects: 51
Study 23124126 — intervention group
Group type: EXPERIMENTAL
Intervention: Open system suctioning (OS)
Number of subjects: 32
Study 23124126 — intervention group
Group type: COMPARATOR
Intervention: Closed system suctioning (CS)
Number of subjects: 32
Study 23124126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OS and CS
Number of subjects: 32
Study 19501822 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera treatment
Number of subjects: 75
Study 19501822 — intervention group
Group type: COMPARATOR
Intervention: Control (normal healthy fertile men)
Number of subjects: 75